

Supplemental Table 1: Urine Biomarker Assay Information

Biomarker	Inter-Assay CV%	Assay (Manufacturer)
Albumin	5.9%	Immunoturbidimetry assay using Siemens Dimension Xpand plus HM clinical analyzer (Siemens, Munich, Germany)
α 1m	13.2%	Siemens BNII nephelometer (Siemens, Munich, Germany)
IL-18	7.2%	ELISA kit (Medical & Biological Laboratories Co., Nagoya, Japan)
KIM-1	5.2%	ELISA kit (R & D Systems, Inc., Minneapolis, MN)
PIIINP	< 10%	ELISA kit (USCN Life Sciences, Wuhan, Hubei, China)

α 1m, alpha-1-microglobulin; CV, coefficient of variation; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; PIIINP, procollagen type III N-terminal propeptide.

Supplemental Table 2: Joint associations of urine albumin and α 1m with annual change in eGFR in HIV-infected and uninfected MACS participants

Urine albumin tertile	Urine α 1m tertile	Annual eGFR change (mL/min/1.73 m ²) (95%CI)	Unadjusted difference (mL/min/1.73 m ²) (95% CI)	Adjusted difference* (mL/min/1.73 m ²) (95% CI)
HIV-infected				
T1 and T2	T1 and T2	-0.23 (-0.87, 0.40)	Reference	Reference
T1 and T2	T3	-2.34 (-3.74, -0.94)	-2.11 (-3.73, -0.49)	-1.43 (-3.05, 0.20)
T3	T1 and T2	-1.92 (-3.96, 0.13)	-1.69 (-3.97, 0.60)	-0.64 (-2.79, 1.51)
T3	T3	-3.64 (-5.03, -2.24)	-3.41 (-5.16, -1.66)	-3.02 (-4.81, -1.23)
Test for urine albumin x α 1m interaction			P=0.12	P=0.09
HIV-uninfected				
T1 and T2	T1 and T2	-0.13 (-0.91, 0.64)	Reference	Reference
T1 and T2	T3	-2.64 (-4.25, -1.02)	-2.50 (-4.48, -0.53)	-2.01 (-3.88, -0.14)
T3	T1 and T2	-1.95 (-5.32, 1.42)	-1.82 (-5.41, 1.77)	-0.66 (-4.05, 2.72)
T3	T3	-3.43 (-5.50, -1.36)	-3.29 (-5.68, -0.90)	-2.09 (-4.38, 0.20)
Test for urine albumin x α 1m interaction			P=0.06	P=0.03

α 1m, alpha-1-microglobulin; eGFR, estimated glomerular filtration rate

*Models adjust for age, race/ethnicity, urine creatinine, baseline eGFR, diabetes mellitus, systolic and diastolic blood pressure, hypertension, cardiovascular disease, low- and high-density lipoprotein cholesterol levels, triglyceride level, body mass index, waist circumference, cigarette smoking status, serum albumin, current heroin use, hepatitis C virus infection.

Supplemental Table 3: Association of urinary biomarkers with annual change in eGFR in HIV-infected MACS participants stratified by TDF use

Biomarker (per doubling)	TDF adjusted difference* (mL/min/1.73 m²/yr) (95% CI)	Non-TDF adjusted difference* (mL/min/1.73 m²/yr) (95% CI)	TDF vs. Non-TDF P-value
Albumin	-0.31 (-0.68, 0.06)	-1.11 (-1.61, -0.60)	<0.01
α1m	-0.44 (-0.99, 0.11)	-0.36 (-1.00, 0.29)	0.83
IL-18	0.43 (0.06, 0.80)	-0.24 (-0.75, 0.27)	0.02
KIM-1	0.25 (-0.26, 0.76)	-0.07 (-0.78, 0.64)	0.42
PIIINP	-0.46 (-1.14, 0.22)	-0.55 (-1.50, 0.39)	0.86

α1m, alpha-1-microglobulin; eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; KIM-1, kidney injury molecule-1; PIIINP, procollagen type III N-terminal propeptide.

Biomarkers modeled individually, not jointly.

*Models adjust for age, race/ethnicity, urine creatinine, baseline eGFR, diabetes mellitus, systolic and diastolic blood pressure, hypertension, cardiovascular disease, low- and high-density lipoprotein levels, triglyceride level, body mass index, waist circumference, smoking status, serum albumin, current heroin use, hepatitis C virus infection